INVESTOR ALERT: Investigation of Carbylan Therapeutics, Inc. Announced by Law Offices of Howard G. Smith, Encourages Investors with Losses to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Carbylan Therapeutics, Inc. ("Carbylan" or the "Company") CBYL concerning the Company and its officers' possible violations of federal securities laws. Injured investors are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights, and a potential class action lawsuit to recover investors' losses.

Carbylan manufactures and commercializes innovative, chemically engineered polymer systems and proprietary combination therapies for such conditions as the treatment of pain associated with osteoarthritis of the knee.

On April 9, 2015, Carbylan held its Initial Public Offering ("IPO"), selling 13 million shares of its stock and generating $65 million in capital. Investors however were allegedly misled regarding the efficacy of the Company's Hydros-TA treatment for knee pain; and, on February 1, 2016, Carbylan announced its top-line results from its first Phase 3 trial of Hydros-TA for the treatment of knee pain connected with osteoarthritis. The Company announced that only one of two primary endpoints had been achieved in the Phase 3 trial.

On this news, Carbylan shares fell $1.81 per share, or over 73%, to close on February 2, 2016 at $0.66 per share.

If you purchased Carbylan securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160401005644/en/